Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

6564

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Artery Disease

Interventions

DRUG: Rivaroxaban (Xarelto, BAY59-7939)
DRUG: Rivaroxaban-Placebo

Sponsor

Bayer

Collaborators

[object Object]
[object Object]